奥扎格雷钠联合灯盏花素治疗急性脑梗死的系统评价  

Efficacy and Safety of Ozagrel Sodium Combined with Breviscapinun in the Treatment of Acute Cerebral Infarction: A Systematic Review

作　　者：范燕[1] 许静[1] 孙晓[1] 

机构地区：[1]江苏省连云港市第一人民医院药学部,江苏连云港222002

出　　处：《中国医院用药评价与分析》2014年第10期890-893,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:系统评价奥扎格雷钠联合灯盏花素治疗急性脑梗死(ACI)的疗效和安全性。方法:检索Cochrane图书馆、PubMed、EMbase、万方医学数据库、中国知网和维普数据库等,纳入奥扎格雷钠联合灯盏花素治疗ACI的随机对照试验(RCT),并手工检索其他相关文献,对纳入研究进行方法学质量评价,并采用RevMan 5.2统计软件进行荟萃分析(Meta分析)。结果:共纳入17项RCT,合计1 641例患者。Meta分析结果显示,奥扎格雷钠联合灯盏花素治疗ACI的神经功能缺损临床疗效比值比(OR)合并值为3.90(95%可信区间为2.87~5.31);神经功能缺损评分疗效加权均数差(WMD)合并值为-4.20(95%可信区间为-5.21^-3.19)。结论:奥扎格雷钠联合灯盏花素治疗ACI临床疗效显著,未见明显不良反应。由于纳入研究的质量不高,结论仍需要更多高质量、多中心的RCT提供有力证据。OBJECTIVE：To systematically evaluate the efficacy and safety of Ozagrel Sodium combined with Breviscapinun in the treatment of acute cerebral infarction （ACI）. METHODS： The randomized controlled trials （RCTs） about Ozagrel Sodium plus Breviscapinun in the treatment of acute cerebral infarction were retrieved from Cochrane library, PubMed, EMbase, Wanfang Data, CNKI and VIP databases, meanwhile other relative literature was retrieved manually. Quality assessment about the methodology of the included studies was performed and meta-analysis of included studies was performed using Review Manager 5.2 software. RESULTS ： Seventeen randomized controlled trials involving 1 641 patients were included. The meta-analysis showed the combined value of odds ratio（OR） was 3.90（95% CI =2.87 -5.31 ）for the clinical efficacy of Ozagrel Sodium combined with Breviscapinun in the treatment of neurologic impairment in patients with acute cerebral infarction（ACI） and the combined value of the weighted mean difference （ WMD ） was - 4. 20 （ 95% CI = -5.21- -3.19 ）. CONCLUSIONS ： Ozagrel Sodium plus Breviscapinun showed remarkable clinical efficacy and good safety for ACI. Due to the inferior quality of the included studies, more multi-center RCTs of high quality are needed to support this conclusion.

关 键 词：奥扎格雷钠 灯盏花素 急性脑梗死 META分析 

分 类 号：R971[医药卫生—药品]